GlassScriptPhysician profile
Harresh B Dulamal
NPI 1699773457
$3,287.23
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $609 · 2021: $977 · 2022: $774 · 2023: $22.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $625.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $453.75 | 2019-2022 | |
| Pfizer INC. | $397.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.25 | 2019-2022 | |
| Amarin Pharma, INC. | $206.03 | 2019-2022 | |
| Amgen INC. | $188.05 | 2019-2022 | |
| Astellas Pharma US INC | $183.27 | 2019-2021 | |
| Lilly USA, LLC | $109.26 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $106.10 | 2019-2021 | |
| Abbvie INC. | $100.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $78.89 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $63.22 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.69 | 2022 | |
| Boston Scientific Corporation | $55.01 | 2019-2023 | |
| Esperion Therapeutics, INC. | $52.95 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.03 | 2021 | |
| Genentech USA, INC. | $50.49 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.62 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.80 | 2019 | |
| Hologic Sales and Service, LLC | $19.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2022 | |
| Lifescan, INC. | $16.39 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.56 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.45 | 2020 | |
| Shield Therapeutics INC | $14.26 | 2022 | |
| Eisai INC. | $14.24 | 2021 | |
| Sanofi Pasteur INC. | $13.83 | 2020 | |
| Horizon Therapeutics Plc | $13.69 | 2019 | |
| Hikma Pharmaceuticals USA | $13.43 | 2020 | |
| Paratek Pharmaceuticals, INC. | $12.95 | 2022 | |
| Ibsa Pharma INC. | $11.91 | 2021 | |
| Glaxosmithkline, LLC. | $11.78 | 2021 | |
| Aytu Biopharma, INC. | $11.67 | 2020 | |
| Endo Pharmaceuticals INC. | $11.60 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harresh Dulamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.